Parkinson's disease

[FASEB Journal] To explore the role of tristetraprolin in Parkinson's disease (PD), an in vitro 1‐methyl‐4‐phenylpyridinium cell model and an in vivo 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine of PD were used.

[Frontiers in Neurology] The authors review existing protocols to generate human midbrain organoids, how they have been used so far to model Parkinson's disease. address challenges inherent to organoid cultures, and discuss applicable strategies to dissect the molecular pathophysiology of the disease.

[Scientific Reports] The authors reveal an important role for astrocytes in Parkinson's disease pathology and highlight the potential of iPSC-derived cells in disease modeling and drug discovery.

[MODAG] MODAG announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. Based on the positive Phase I study results, MODAG was also able to obtain additional funding of USD 1.4 million from The Michael J. Fox Foundation for parkinson's research.

[Scientific Reports] Researchers report fundamental changes in biodistribution and brain bioavailability of macrophage-based formulations upon different routes of administration: intravenous, intraperitoneal, or intrathecal injections.

[EMBO Journal] Scientists showed that the Parkinson's disease‐related kinase LRRK 2 was activated in macrophages by pathogen‐ or sterile‐induced endomembrane damage.